found at page 29, lines 7-10. Support for new claims 27-32 can be found at page 11, lines 2-13 and page 12, lines 4-5. Support for new claim 33 can be found at page 32, lines 27-29. Support for new claim 34 can be found at page 32, lines 18-21 and 27-29.

Entry of the above amendment is respectfully requested prior to the examination of this application.

Following entry of the amendment, claims 1-34 are presented for examination in this case. Favorable consideration and an early action on the merits is respectfully requested.

Respectfully submitted,

Dated: February 27, 2003

Paul F. Fehlner, Ph.D.

Reg. No. 35,135

Agent for Applicant(s)

DARBY & DARBY, P.C. Post Office Box 5257 New York, NY 10150-5257 Phone (212) 527-7700

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper or, if this paper is a transmittal letter, every other paper or fee referred to therein, is being facsimile transferred to the Commissioner for Patents & Trademarks at the United States Patent and Trademark Office, Washington, DC 20231, on the date shown below.

Signature

DEPOSIT ACCOUNT NO. 04 - 0100

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY

EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR

date indicated above this paper or

fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents Washington, DC 20231 by Express to Addressee" service

Signature 7210

Docket No: 7529/1F590-US1

Customer No.:

Patent Trademark Office

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Ralph M. STEINMAN, Christan MUENZ

MAR 1 8 2003

Serial No.:

10/049,316

Art Unit:

1645

TECH CENTER 1600/2900

Filed: 02/08/2002

Examiner:

Not yet assigned

For:

PROTECTIVE ANTIGEN OF EPSTEIN BARR VIRUS

MARK-UP FOR PRELIMINARY AMENDMENT OF FEBRUARY 27, 2003

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

February 27, 2003

Sir:

Pursuant to 37 C.F.R. §1.121, applicants provide the following mark-up copy of the amended claims in the above-referenced application.

IN THE CLAIMS

6. (Amended) The vector of claim [6] 5 which preferentially targets dendritic cells.

{M: 7529.1f590.PMZ0120.DOC *7529.1F590*}

7. (Amended) The vector of claim [6] 5, wherein the polypeptide is a fusion polypeptide comprising an amino acid sequence of EBNA-1 and a heterologous amino acid sequence.

8. (Amended) The vector of claim $[6] \underline{5}$ which is a viral vector.